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Clinical Perspectives 
i) Inflammatory bowel disease remains a major clinical problem, as current therapies 
available to treat these collection of disease carry significant side effects. Cannabis-based 
medicines have been used informally to treat colonic inflammation for many years, however 
investigation into the therapeutic utility of these drugs has only recently been undertaken. We 
therefore sought to quantify the anti-inflammatory properties of two cannabinoid drugs, 
cannabidiol (CBD) and palmitoylethanolamide (PEA) in the inflamed human colon.  
ii) We found that CBD and PEA agents demonstrate significant anti-inflammatory actions in 
experimentally and clinically inflamed colon reducing the production of multiple key pro-
inflammatory cytokines, and down regulating pro-inflammatory intracellular pathways.  
iii) As these two drugs are well tolerated in humans with few side effects, their clinical use in 
treating inflammatory bowel disease is expected.  Appropriately seized clinical trials should 
now assess their clinical efficacy.   
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ABSTRACT 
 
Objective: We sought to quantify the anti-inflammatory effects of two cannabinoid drugs: 
cannabidiol (CBD) and palmitoylethanolamide (PEA), in cultured cell lines and compared 
this effect with experimentally inflamed explant human colonic tissue.  These effects were 
explored in acutely and chronically inflamed colon, using inflammatory bowel disease and 
appendicitis explants. 
Design: Caco-2 cells and human colonic explants collected from elective bowel cancer, 
inflammatory bowel disease (IBD) or acute appendicitis resections, and were treated with the 
following drug treatments: vehicle, an inflammatory protocol of IFNγ and TNFα (10 ng/ml), 
inflammation and PEA (10µM), inflammation and CBD (10µM), & PEA or CBD 
alone.  PEA, CBD or vehicle were added simultaneously with IFNγ. Nine intracellular 
signalling phosphoproteins were determined by multiplex.  Inflammatory cytokine secretion 
was determined using ELISA.  Receptor mechanisms were investigated using antagonists for 
CB1, CB2, PPARα, PPARγ, TRPV1 and GPR55. 
Results:  IFNγ and TNFα treatment increased phosphoprotein and cytokine levels in Caco-2 
cultures and colonic explants.  Phosphoprotein levels were significantly reduced by PEA or 
CBD in Caco-2 cultures and colonic explants.  CBD and PEA prevented increases in cytokine 
production in explant colon, but not in Caco-2 cells. CBD effects were blocked by the 
CB2antagonist AM630 and TRPV1 antagonist SB366791.  PEA effects were blocked by the 
PPARα antagonist GW6471.  PEA and CBD were anti-inflammatory in IBD and appendicitis 
explants. 
5 
 
Conclusion: PEA and CBD are anti-inflammatory in the human colon.  This effect is not 
seen in cultured epithelial cells.  Appropriately sized clinical trials should assess their 
efficacy.   
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INTRODUCTION 
In health, the gut absorbs nutrients from the lumenal environment into the sterile submucosa 
without absorbing noxious material, such as bacteria and lipopolysaccharide.   The barrier 
between lumen and submucosa is formed by epithelial cells, which allow selective absorption 
of particles into the enteric circulation via paracellular and transcellular pathways, whilst 
preventing bacterial translocation (1–5).  Inflammation causes this barrier to become 
compromised (6). Inflammation is caused by conditions such as diverticulitis, infective colitis 
and appendicitis, and also inflammatory bowel disease (IBD), such as ulcerative colitis and 
Crohn’s disease (7).  When inflammation occurs, lumenal bacteria and lipopolysaccharide are 
able to translocate into the submucosal space and beyond, resulting in secondary 
complications such as endotoxaemia, sepsis and death (there are 30,000 deaths from sepsis 
per year in the UK alone) (8,9).  Currently, there are no clinical treatments to counter 
permeability changes seen in systemic inflammation and sepsis. Development of an agent to 
prevent bacterial and lipopolysaccharide translocation across the gut wall with the intention 
of reducing or preventing the triggering of sepsis is therefore of high clinical importance.   
We have previously demonstrated, in Caco-2 culture models, that inflammation stimulated by 
tumour necrosis factor alpha (TNFα) and interferon gamma (IFNγ) increases epithelial 
permeability, shown by falls in trans-epithelial electrical resistance (TEER) (10).  The non-
pyschotrophic constituent of cannabis sativa, cannabidiol (CBD), and the endogenous fatty 
acid amide palmitoylethanolamide (PEA) prevented these changes when used 
prophylactically, and restored membrane resistance when given therapeutically, acting via the 
CB1 and PPARα receptors respectively (10,11).  Others have also observed a protective effect 
of PEA and CBD on the gut barrier during inflammation (12,13). 
What is not clear is the mechanism by which PEA and CBD modify permeability during 
inflammation.  Recently we showed that PEA may act through modification of the actin 
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cytoskeleton by inducing FAK production and down regulating  aquaporins 3 and 4, but it 
was not clear if this was secondary to an anti-inflammatory effect of PEA or due to direct 
action of  PEA (14).  PEA and CBD exert an anti-inflammatory effect on enteric glial cells, 
which can modify the immune response in vivo (15–18),  therefore any in vivo permeability 
effects may indeed be secondary to an anti-inflammatory effect rather than direct action on 
cellular structures which contribute to regulation of permeability.       
 
Previous studies have shown both PEA and CBD to blunt increases in permeability in 
experimentally inflamed explant colonic tissue (17–19).  As the extent of the anti-
inflammatory effect of PEA and CBD in vitro and in vivo has not yet been quantified, we 
examined the effect of PEA and CBD on the local inflammatory response in cultured Caco-2 
cells and explant human colonic tissue.  We hypothesised that CBD and PEA cause changes 
in intestinal permeability through suppression of the local immune response.  We therefore 
examined the effect of CBD and PEA on the intracellular signalling phosphoproteins in 
response to inflammation, and on down-stream production of inflammatory cytokines.   This 
allowed us to compare the effects of PEA and CBD on the epithelium alone, to their effect on 
whole tissue.  In order to assess the effect of CBD and PEA on clinically inflamed colonic 
tissue we examined the effects of these drugs on explant colon from patients with established 
inflammation caused by acute appendicitis and inflammatory bowel disease. 
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MATERIALS AND METHODS 
All experiments and procedures received prior approval of the University of Nottingham 
Ethics Committee and local NHS Research Ethics Committee.   
Caco-2 Cell Culture 
Caco-2 cells were purchased from European Collection of Cell Culture (Wiltshire, UK; 
passages 21-42).  Cells were cultured in Eagle’s minimum essential medium supplemented 
with L-glutamine, 10% foetal bovine serum (FBS) 1% penicillin/streptomycin and 1% non-
essential amino acids mixture (all Sigma-Aldrich).  Cells were kept at 37°C in 5% CO2 and 
95% humidity.  Cells were seeded at 4x105 cells per well in polystyrene 12 well plates 
(Corning Incorporated, USA), and grown for 2 weeks until fully differentiated.  Cells were 
used for experimentation at day 14-16.  The medium was changed on alternate days. 
Randomly assigned wells (n=8) were treated with the following drug treatments: vehicle, an 
inflammatory protocol of IFNγ (10ng.ml-1, Sigma-Aldridge) for 8 hours, followed by TNFα 
(10ng.ml-1, Sigma-Aldridge) for 16 hours, inflammation and PEA (10µM, PEA was added 
simultaneously with IFNγ at the start of the 24 hour inflammatory period), inflammation and 
CBD (10µM, CBD was added simultaneously with IFNγ at the start of the 24 hour 
inflammatory period), PEA (10µM) alone, or CBD (10µM) alone.  PEA and CBD were 
purchased from Tocris Bioscience (Bristol, UK).  At the end of the 24 hour experimental 
period, media was collected and stored at -80 °C until analysis.  Cells were washed twice 
with ice-cold phosphate-buffered saline (PBS), and treated with radioimmunoprecipitation 
assay (RIPA) buffer supplemented with phosphatase and protease inhibitors (Sigma-
Aldridge) at 4°C for one hour on a rocking platform to cause cell lysis.  Cell lysates were 
then collected and stored at -80 °C until analysis. 
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Human Colon Experimentation 
Experiments on ex vivo human tissue were performed by obtaining colonic samples from 
patients having elective bowel resections for bowel cancer (n=13), planned resections for 
quiescent inflammatory bowel disease (n=6) or emergency appendectomies for acute 
appendicitis (n=6) at Derby Teaching Hospitals NHS Trust, Derbyshire, UK. Samples of 
normal colon at least 10cm proximal to right sided bowel tumours (in the case of bowel cancer 
resections), sections of inflamed colon (in inflammatory bowel disease resection), or sections 
of inflamed appendix (in the case of emergency appendicectomy) were obtained immediately 
after resection in the operating theatre.  Sections of tissue 2cm x 2cm were removed from the 
resected specimen and transferred on ice to the laboratory within ten minutes, in pre-chilled 
Eagle’s minimum essential medium supplemented with 1% FBS 1% penicillin/streptomycin 
and 1% non-essential amino acids mixture (Sigma-Aldrich).  The remaining operative 
specimen was sent to pathology for routine analysis. Once in the laboratory samples were 
pinned on Stylgard plates. Mucosa with submucosa was dissected free from the underlying 
muscularis layer.  Mucosal samples were then further dissected into 2mm x 2mm sections and 
placed in individual wells of 24-well polystyrene plates (Corning Incorporated, USA), each 
containing 1ml of media.  Samples of colonic tissue were then treated with TNFα and IFNγ, in 
the absence or presence of PEA and CBD as described above within Caco-2 experiments.  
Experiments were carried out in triplicate, with final values derived from the mean result of 
three measurements.  Samples were incubated for 24 hours at 37°C in 5% CO2 and 95% 
humidity.  At the end of the 24 hour experimental period media was collected and stored at -
80 °C until analysis.  Explant tissue was washed with ice cold PBS and stored frozen at -80 °C 
until homogenisation and analysis.  Prior to analysis colonic samples were thawed on ice and 
cryohomogenised using the method described by von Ziegler (20).  Collected homogenates 
were then dissolved in 215µl of RIPA buffer, incubated on an oscillating thermomixer for 30 
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minutes at 60 °C, then centrifuged at 10,000G for 15 minutes.  Supernatant was collected, 
vortexed for 20 seconds and then analysed. 
Intracellular signalling pathways 
To determine the effect of CBD and PEA on signalling proteins, Luminex xMAP technology 
(Austin, TX, USA) was used to detect changes in phosphorylated cAMP response element-
binding protein (CREB; pS133), ERK (pT185/pY187), NF-kB (pS536), JNK (pT183/pY185), 
p38 (pT180/pY182), p70 S6K (pT412), STAT3 (pS727), STAT5A/B (pY694/699), and Akt 
(pS473) (Milliplex 48-680MAG; Merck Millipore, Darmstadt, Germany) from undiluted cell 
lysates or homogenised colonic lysates according to the manufacturer’s instructions using a 
Magpix plate reader (MAGPX 11326002, Luminex, Texas, US).  Signalling phosphoprotein 
concentrations were corrected for total protein content using the bicinchoninic acid (BCA) 
assay determination of cell lysate protein concentration against a standard curve.   
Cytokine production  
We measured specific proteins induced as a consequence of TNFα stimulation.  To quantify 
the effects of PEA and CBD on the inflammatory response we measured media concentrations 
from cell or colonic cultures of seven cytokines at the end of the 24 hour experimental period 
using ELISA.  Cytokines measured were interleukin-8 (IL-8), monocyte chemoattractant 
protein-1 (MCP-1), intercellular adhesion molecule-1 (ICAM-1), matrix metallopeptidase-3 
(MMP-3); DUOSET ELISA kits R&D Systems Minneapolis, US. Interleukin-17 (IL-17), 
granulocyte-macrophage-colony stimulating factor (GM-CSF), interleukin-6 (IL-6); ready-set-
go ELISA kits, Affymetrix eBioscience, San Diego, CA. Cytokine concentrations were 
normalised for protein content as previously using BCA assay determination of cell lysate 
protein concentration against a standard curve.  Experimental conditions were averaged from 
triplicate readings, as above.  
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Target sites of action of PEA & CBD 
To identify target sites of action of PEA and CBD we co-applied the following antagonists to 
healthy colonic explant tissue with PEA or CBD under inflammatory conditions: AM251 
100nM (CB1 antagonist, Tocris Bioscience, Bristol, UK), AM630 100nM (CB2 antagonist, 
Tocris Bioscience, Bristol, UK), GW6471 500nm (PPARα antagonist, Tocris Bioscience, 
Bristol, UK), GW9662 100nM (PPARγ antagonist, Tocris Bioscience, Bristol, UK), SB366791 
500nM (TRPV1 antagonist, Tocris Bioscience, Bristol, UK), and CID16020046 500nM (GPR55 
antagonist, Tocris Bioscience, Bristol, UK).  Following co-incubation for 24 hours, media 
concentrations of IL-8 and MCP-1 were measured using ELISA.  IL-6 concentrations were 
measured using ready-set-go ELISA kits (Affymetrix eBioscience, San Diego, CA). 
Statistical Analysis 
Data are presented as mean (or mean percentage change from baseline where indicated) ± 
SEM.  Caco-2 cytokine and signalling protein concentration results were compared using 
one-way ANOVA.  Human tissue cytokine secretion and phosphorylated protein levels are 
expressed as percentage change compared to vehicle per patient or [pg/ml]/[mg/ml] where 
indicated, and analysed using repeated measures ANOVA. For human tissue, each value 
represents the mean of three independent values. A p-value of <0.05 was considered 
statistically significant.  All statistical analyses were performed using GraphPad Prism 7.01 
for Windows (GraphPad Software, San Diego, USA). 
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RESULTS 
Intracellular response to inflammation 
Stimulation of Caco-2 cells with IFNγ and TNFα significantly increased the levels of CREB, 
JNK, NF-KB, p38, ERK1/2, Akt, p70S6k, STAT3, and STAT5 (figure 1).  CBD, in the 
presence of inflammation compared to inflammation alone, prevented the production of 
CREB (p=0.002), p38 (p=0.08), NF-κB (p=0.009), JNK (p=0.02), p70S6K (p=0.07), Akt 
(p=0.08), STAT3 (p=0.06) and STAT5 (p=0.03).   PEA in the presence of inflammation, 
compared to inflammation alone, prevented increases in CREB (p=0.01), JNK (p=0.01) and 
STAT5 (p=0.08). CBD or PEA treatment alone did not affect the level of any of the 
phosphorylated proteins compared to control tissue.   
Stimulation of explant colonic tissue with IFNγ and TNFα resulted in an increase in all of the 
measured signalling phosphoproteins (figure 2).  PEA in the presence of inflammation, 
compared to inflammation alone, prevented increases in CREB (p=0.055), NF-κB (p=0.007), 
Akt (p=0.002), p70S6K (p=0.005), STAT3 (p=0.01) and STAT5 (p=0.007).  CBD in the 
presence of inflammation, compared to inflammation alone, prevented increases in STAT3, 
though did not reach significance (p=0.09).  PEA or CBD alone did not affect the production 
of any phosphoprotein compared to vehicle. 
Effects of PEA and CBD on cytokine production in response to inflammation 
Stimulation of Caco-2 cells with IFNγ and TNFα caused an increase in the secretion of IL-8 
and IL-6 although did not increase in the secretion of IL-17 (figure 3).  In human colonic 
tissue IFNγ and TNFα caused and increase in the production of IL-8, IL-6 and IL-17 (figure 
3).  Both PEA and CBD did not affect the production of these cytokines in Caco-2 cultures, 
but did prevent their increased in human colonic explants. 
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Stimulation of Caco-2 cells with the inflammatory protocol did not increase the production of 
GM-CSF, but both PEA alone and CBD alone increased GM-CSF production in the absence 
of inflammation (figure 4).  In human tissue IFNγ and TNFα stimulation increased the 
production of GM-CSF which was prevented by CBD but not PEA (figure 4).   
IFNγ and TNFα markedly increased MCP-1 production by Caco-2 cells and human colonic 
tissue (figure 4).  CBD and PEA had no effect on Caco-2 production of MCP-1, but did 
significantly reduce production in human tissue. 
Stimulation of Caco-2 cells with IFNγ and TNFα increased the production of ICAM-1 (figure 
5, A).  CBD and PEA did not prevent this increase in production, but PEA alone caused a 
marked increase in ICAM-1 production compared to vehicle.  In human colonic tissue, an 
increase in ICAM-1 caused by IFNγ and TNFα was prevented by the administration of PEA 
(figure 5, C).  Treatment of inflammation-stimulated colonic tissue with CBD also decreased 
production, though did not reach significance. PEA alone, CBD in the presence of 
inflammation and CBD alone had no effect on ICAM-1 production in colonic tissue 
compared to vehicle. 
Stimulation of Caco-2 cells with IFNγ and TNFα had no effect on the production of the 
enzyme MMP-3 (figure 5, B).  In human tissue the inflammatory protocol did not 
significantly increase the production of MMP-3, however both PEA and CBD did 
significantly reduce its production in the presence of IFNγ and TNFα (figure 5, D). 
Antagonist studies  
When investigating for a receptor mechanism for PEA and CBD we found again that 
stimulation of colonic explant tissue with the inflammatory protocol caused a significant rise 
in IL-8, IL-6 and MCP-1 production compared to baseline, whilst treatment of inflamed 
colon with simultaneous PEA or CBD prevented these increases in cytokine production 
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(figure 6, A to F).  The anti-inflammatory effects of PEA on IL-8, IL-6 and MCP-1 
production were prevented by the addition of the PPARα antagonist GW6471.  The anti-
inflammatory effects of CBD on IL-8, IL-6 and MCP-1 production were prevented by the 
CB2 antagonist AM630.  The anti-inflammatory effects of CBD on IL-8 and MCP-1 
production were also inhibited by the addition of the TRPV1 antagonist SB366791.  
SB366791 had no effect on the anti-inflammatory effect of CBD in the presence of 
inflammation.  GW6471, AM630 and SB366791 had no effect on cytokine production in the 
presence of IFNγ and TNFα alone (data not shown). 
Effects of PEA and CBD on cytokine production in response to inflammation in IBD 
colonic explants 
Because we found PEA and CBD had an anti-inflammatory effect on experimentally 
inflamed tissue we collected samples of inflamed colon from patients with IBD and acute 
appendicitis. 
Explants of six patients with quiescent IBD were collected.  IBD colonic explants 
demonstrated significantly higher levels of all measured cytokines, in comparison to vehicle-
treated sections of healthy tissue.  Treatment of IBD explants with inflammatory cytokines 
further increased the secretion of IL-8, IL-6, IL-17, GM-CSF, MCP-1 and ICAM-1 (figure 7), 
but not MMP-3.  Treatment of cytokine-stimulated tissue with PEA and CBD supressed this 
increased secretion of inflammatory mediators (figure 7).  Treatment of unstimulated IBD 
tissue with either PEA or CBD alone produced a trend of decreased inflammatory cytokine 
secretion, however this only reached significance in the case of IL-6 in CBD-treated tissue. 
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Effects of PEA and CBD on cytokine production in response to inflammation in 
appendicitis explants 
Explants of six patients with acute appendicitis were collected.  Appendicitis explants 
secreted significantly higher baseline levels of all measured cytokines compared to healthy 
colonic tissue.  Treatment of appendicitis explants with cytokines caused an increase in the 
secretion of inflammatory cytokines, though this only reached significance in GM-CSF, 
MCP-1 and ICAM-1 (figure 8).  Treatment of cytokine-stimulated appendicitis tissue with 
PEA decreased the secretion of IL-8, IL-6 and MCP-1 compared to appendicitis tissue 
stimulated with cytokines alone.  Treatment of cytokine-stimulated appendicitis tissue with 
CBD decreased the secretion of MCP-1 compared to appendicitis tissue stimulated with 
cytokines alone.  Compared to vehicle-treated appendicitis tissue, PEA alone significantly 
supressed the secretion of IL-8, IL-6, MCP-1 and ICAM-1.  Compared to vehicle-treated 
appendicitis tissue, CBD alone significantly supressed the secretion of GM-CSF, MCP-1 and 
ICAM-1. 
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DISCUSSION 
The aim of this study was to examine the anti-inflammatory properties of PEA and CBD in 
Caco-2 cell lines and explant human colonic tissue.  We demonstrate that under inflammatory 
conditions, PEA and CBD supress the phosphorylation of several intracellular proteins in 
Caco-2 cells, however this does not supress the secretion of pro-inflammatory cytokines.  
Conversely, in explant human colonic tissue stimulated with IFNγ and TNFα, PEA and CBD 
both supressed the phosphorylation of intracellular proteins which were up-regulated by 
inflammation, and also prevented the increased secretion of pro-inflammatory cytokines.  
Additionally we have shown that PEA and CBD have an anti-inflammatory effect in explant 
IBD and appendicitis tissue. 
Caco-2 cell cultures 
We previously demonstrated that CBD and PEA prevent changes in the permeability of 
Caco-2 monolayers under inflammatory conditions.  Prior to this study we had hypothesized 
that this effect on permeability was secondary to a local anti-inflammatory action, as it had 
been seen in work from other centres that CBD and PEA supress the inflammatory response 
in the inflamed colon of mice and humans (17,18,21–23).  For this hypothesis to be correct 
we would expect PEA and CBD to have an anti-inflammatory action in Caco-2 monolayers.  
IFNγ and TNFα, caused a significant increase in all measured intracellular signalling 
proteins, in line with similar experiments using TNFα stimulation on Caco-2 cell lines (24).  
We found that increases were suppressed by PEA and CBD.   It is possible that both of these 
effects could be due to increased anandamide (AEA) tone. PEA has been shown to increase 
the action of local AEA either by preventing hydrolysis of AEA through substrate 
competition or FAAH inhibition (25), or by enhancing AEA potency at villanoid receptors 
(26).  Secondly CBD has been shown to prevent AEA uptake and catabolism (27).   AEA 
itself has been shown to down regulate NF-KB and exert anti-inflammatory properties 
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through IL-10, and may therefore been at least partly responsible for these effects on signal 
phosphorylation (28).   We then quantified the effect of PEA and CBD on the extracellular 
inflammatory response, measuring seven pro-inflammatory cytokines representing five 
aspects of immune activation. As an indicator of pro-inflammatory cytokine production we 
assayed IL-8, IL-6, and IL-1 (29–31).  As a marker of leucocyte recruitment and activation 
we assayed MCP-1 and GM-CSF (32,33). As a marker of extracellular matrix remodelling 
we measured MMP-3 concentrations (34), and as a marker of cell-to-cell adhesion we 
measured concentrations of ICAM-1.  We found that stimulation of Caco-2 cultures with 
IFNγ and TNFα caused an increase in all measured cytokines, except MMP-3.  Surprisingly, 
neither PEA nor CBD prevented the increased secretion of these cytokines.  We may suggest 
therefore that the effects of PEA and CBD on signal phosphorylation and permeability are 
distinct from their effects on inflammation, and not due to suppression of a local extracellular 
immune response. 
Ex vivo Colonic Tissue 
In explant human tissue we found that the local inflammatory response caused by stimulation 
with IFNγ and TNFα was inhibited by treatment with PEA and CBD.  This finding, in 
contrast to results in cultured Caco-2 cells, could be explained by the presence of submucosal 
immunocytes such as dendritic cells and macrophage activity.  Explant colonic samples 
contain lymphoid aggregates and innate immune cells, as opposed to monolayers of Caco-2 
cells (35).  It has previously been described that within the gut the CB2 receptor, AEA and 2-
AG are found in highest abundance within these submucosal immune and also nervous 
tissues such as enteric glial cells, and that this may be the primary site of endocannabinoid 
activation during inflammatory episodes (12,36).  Within our colonic explant tissue PEA and 
CBD may be acting on such macrophage and dendritic cell colonies, thus supressing the local 
inflammatory response (35,37).  This would explain why cytokine secretion was decreased in 
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the presence of IFNγ and TNFα, but no decrease was found in tissue treated with PEA or 
CBD alone, compared to vehicle treated tissue.  Further work therefore could examine the 
effect of CBD and PEA on Caco-2 cells in a co-culture model exploring possible receptor 
mechanisms in these specialised tissues. 
Receptor sites of PEA and CBD are not clear.  Capasso et al. (2001) first demonstrated that 
the action of PEA on gut hypermotility in mice caused by caustic inflammation (croton oil), 
was prevented by blockade of the CB2, but not CB1 receptor. (38) The same group also 
reported that in a different model of hypermotility (oil of mustard), PEA had an anti-
inflammatory effect that was inhibited by blockade of the CB1 and PPARα receptors, but not 
by blockade of CB2. (39)  Esposito et al. demonstrated that anti-inflammatory effects of PEA 
in both dextran-sulphate sodium treated mice and colonic biopsies from patients with 
ulcerative colitis were inhibited by blockade of the PPARα receptor (18).  As mentioned 
above, it has been suggested that PEA may exert its effects through increasing the local 
concentration or potency of a second agent, such as anandamide, and therefore antagonising 
receptor targets of PEA or the second agent would inhibit their biologic effects (40).  In view 
of this we examined the anti-inflammatory effect of PEA in the presence of six receptor 
antagonists at which cannabinoid agonists have been postulated to act; CB1, CB2, PPARα, 
PPARγ, TRPV1 and GPR55.  We found that across three measured cytokines the effect of 
PEA was prevented by antagonism of PPARα.   This is the second human colonic study to 
demonstrate PEA action at PPARα, suggesting that this PEAs primary site of action in 
colonic mucosa (14).   
Similarly, multiple studies have suggested various sites of action of CBD in the mammalian 
gut.  Two murine studies demonstrating the beneficial effect of CBD on inflammation-
induced effects on gut transport showed that CB1 rather than CB2 was the target receptor of 
CBD (41,42).  However two independent studies examining the effect of CBD on the 
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immune response in human and murine colonic tissue suggested that PPARα was the 
dominant receptor target of CBD, with a possible role for CB1, but again suggesting that CB2 
was not a receptor target (17,43).  However our data show a role for CB2 and TRPV1.  It is 
possible than these data differ from pre-existing literature because of site of colonic sampling 
and mode of inflammation used for simulating colitis.  It has been demonstrated that the 
distribution of endocannabinoid receptors and differs across the colon, and that these 
receptors are activated by inflammation.  Within our study we collected colonic samples from 
right sided colonic resections, whereas mouse-colonic studies previously cited have used 
whole colonic homogenates, and the pre-existing human colon studies have used left-sided 
(sigmoid) colonic biopsies.  It is possible therefore the sites of CBD activation differ 
throughout the gut, hence in the proximal gastrointestinal tract PPARα is the pre-dominant 
site of activation, whereas distally CB2, TRPV1 and then CB1 become more important.  This 
may be supported by evidence showing that in established inflammation of the gut and other 
organ systems CBD has epithelial protective effects medicated by CB2 and TRPV1 (44,45).  
One study in particular found that during a murine model of colitis-induced sepsis, CBD 
prevented peripheral organ oxidation, further demonstrating the effect of CBD on epithelial 
barriers during sepsis (46).  Further work could compare the receptor targets of CBD across 
the gut, using a similar model of inflammation.   
We then compared the anti-inflammatory effect of PEA and CBD in experimentally inflamed 
normal colonic tissue, explant IBD tissue, and explant appendicitis. We found that although 
appendicitis tissue had higher baseline levels of cytokine production, similar increases in 
cytokine secretion was caused by IFNγ and TNFα treatment in all three tissue types.  These 
differences in baseline cytokine production are likely to represent the acute inflammatory 
nature of acute appendicitis, versus the chronic low-levels of inflammation in long-standing 
IBD, compared with healthy tissue.  CBD and PEA were strongly anti-inflammatory in acute 
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appendicitis tissue, but not paralleled in IBD tissue.  We also did not find that PEA and CBD 
were effective in preventing increased cytokine production in cytokine-treated IBD and 
appendicitis tissue.  This may suggest that the receptor profile in acute inflammation differs 
from that in long-standing chronic inflammation, and therefore any benefit seen in IBD may 
not be secondary to an anti-inflammatory effect, and may be secondary to effects on mucosal 
permeability.  This is supported by a clinical study from Naftali et al (2013) who showed an 
improvement in disease activity scores and quality of life in IBD patients receiving cannabis 
sativa cigarettes, though did not find any change in biochemical markers of inflammation 
using serum CRP levels as a marker (13).  Furthermore a study from Di Sabatino (2011) 
conducted in a similar explant manner found differences in the expression of 
endocannabinoid ligands between control and inflamed IBD explants, the inflammatory 
response of which was down regulated with the addition of methanandamide (47).  A recent 
study from the same centre used low dose CBD in inflammatory bowel disease, though did 
not find any benefit in improving quality of life scores (48).  Before drawing conclusions 
however regarding the efficacy of CBD in IBD it is important to highlight that this study may 
have been hampered by small group sizes and the ultra-low doses of CBD employed.  
This study provides further evidence that PEA and CBD may play a role in the treatment of 
acute inflammation of the gut, including Crohn’s and ulcerative colitis. Our data are limited 
by using explant tissue, rather than any clinical in vivo data, and the generic nature of the 
explant models used.  Furthermore we did not carry out tissue viability assays on explant 
tissue to ensure the mucosa had not been damaged by dissection, or had become necrotic.  
Further clinical work examining the use of these two drugs in the treating inflammatory 
disease of the gut should now be considered.  Additionally we have hypothesized that the 
effects of CBD and PEA on signal phosphorylation and the inflammatory response may be 
due to increased efficacy or presence of AEA.  Further work should now be conducted within 
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both Caco-2 models and healthy colon, appendicitis and inflammatory bowel disease explants 
to quantify the effect of CBD and PEA on endocannabinoid production.  Lastly within this 
study we did not examine for any additive effects of CBD together with PEA on the immune 
response, which may have been positive. 
In summary we have demonstrated that CBD and PEA prevent cytokine production in human 
colonic explant tissue via PPARα, CB2 and TRPV1, but not in cultured epithelial cells.  
These effects extend into chronic inflammatory processes such as IBD, but also acute 
inflammatory conditions such as appendicitis.  Further clinical work must examine the effects 
of these two drugs at higher doses, and clarify their clinical role. 
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FIGURE LEGENDS 
 
 
Figure 1 
The effects of PEA and CBD on the intracellular levels of phosphorylated nuclear signalling 
proteins in response to an inflammatory protocol in cultured Caco-2 monolayer, measured by 
multiplex.  Data is presented as percentage change from vehicle per plate +/- SEM, n=8 per 
condition.  Data was analysed by one-way ANOVA comparing against the vehicle control or 
inflammation (*<0.05, **<0.01 and ***<0.001).  
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Figure 2 
The effects of PEA and CBD on the intracellular levels of phosphorylated signalling proteins 
in response to 24hr exposure to TNFα and IFNγ in cultured human colonic explants, 
measured by multiplex.  Data is presented as percentage change from vehicle +/- SEM, n=13 
per condition.  Data was analysed by repeated measures ANOVA comparing against the 
vehicle control (*), *<0.05, **<0.01. 
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Figure 3 
The effects of PEA and CBD on the secreted cytokine response to an inflammatory protocol 
in cultured Caco-2 monolayers (A, C and E, column 1, n=8, percentage change from vehicle, 
one way ANOVA) and human colonic tissue (B, D and F, column 2, n=7, percentage change 
compared to vehicle, repeated measures ANOVA), measured by ELISA.  Error bars represent 
+/- SEM per condition. Asterixes (*) represent significant difference from vehicle, *<0.05, 
**<0.01, ***<0.001. 
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Figure 4 
The effects of PEA and CBD on granulocyte macrophage colony stimulation (A, C) and 
monocyte chemotaxis (B, D) response to an inflammatory protocol in cultured Caco-2 
monolayers (column 1, n=8, percent change from vehicle per plate compared by one-way 
ANOVA) and human colonic tissue (column 2, percentage change from vehicle, N=7, 
compared by repeated measures ANOVA), measured by ELISA.  Error bars represent +/- 
SEM per condition. Asterixes (*) represent significant difference from vehicle, *<0.05, 
**<0.01, ***<0.001, ****<0.0001. 
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Figure 5 
The effects of PEA and CBD on intracellular adhesion (A,D) and matrix metalloproteinase 
secretion (B,D) response to an inflammatory protocol in cultured Caco-2 monolayers (column 
1, n=7, percent change compared by one-way ANOVA) and human colonic tissue (column 2, 
percentage change compared by repeated measures ANOVA), measured by ELISA.  Error 
bars represent +/- SEM per condition. Asterixes (*) represent significant difference from 
vehicle, *<0.05, **<0.01, ***<0.001, ****<0.0001. 
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Figure 6 
The effects of PEA (A,C,E) and CBD (B,D,F) on the secretion of IL-8, MCP-1 and IL-6 in 
response to an inflammatory protocol in explant human colonic tissue in the presence of 
receptor antagonists, measured by ELISA (compared by repeated measures ANOVA, n=7). 
Data presented as mean +/- SEM per condition. Asterixes (*) represent significant difference 
from vehicle, *<0.05, **<0.01. 
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Figure 7 
The effects of PEA and CBD on the secreted inflammatory response in IBD colonic explants 
treated with an inflammatory protocol (n=6, percent change from vehicle, compared by 
repeated measures ANOVA), measured by ELISA. Error bars represent +/- SEM per 
condition. Asterixes (*) represent significant difference from vehicle, *<0.05, **<0.01, 
***<0.001, ****<0.0001.   
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Figure 8 
The effects of PEA and CBD on the secreted inflammatory response in appendicitis explants 
treated with an inflammatory protocol (n=6, percent change from vehicle, compared by 
repeated measures ANOVA), measured by ELISA. Error bars represent +/- SEM per 
condition. Asterixes (*) represent significant difference from vehicle, *<0.05, **<0.01, 
***<0.001, ****<0.0001. 
